Display options
Cite
Link T, Kuithan F, Ehninger A, et al. Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. Oncotarget. 2017;8(33):54592-54603doi: 10.18632/oncotarget.17523.
Link, T., Kuithan, F., Ehninger, A., Kuhlmann, J. D., Kramer, M., Werner, A., Gatzweiler, A., Richter, B., Ehninger, G., Baretton, G., Bachmann, M., Wimberger, P., & Friedrich, K. (2017). Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. Oncotarget, 8(33), 54592-54603. https://doi.org/10.18632/oncotarget.17523
Link, Theresa, et al. "Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression." Oncotarget vol. 8,33 (2017): 54592-54603. doi: https://doi.org/10.18632/oncotarget.17523
Link T, Kuithan F, Ehninger A, Kuhlmann JD, Kramer M, Werner A, Gatzweiler A, Richter B, Ehninger G, Baretton G, Bachmann M, Wimberger P, Friedrich K. Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. Oncotarget. 2017 Apr 29;8(33):54592-54603. doi: 10.18632/oncotarget.17523. eCollection 2017 Aug 15. PMID: 28903367; PMCID: PMC5589606.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Apr 29;8(33):54592-54603. doi: 10.18632/oncotarget.17523. eCollection 2017 Aug 15.

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.

Oncotarget

Theresa Link, Friederike Kuithan, Armin Ehninger, Jan Dominik Kuhlmann, Michael Kramer, Andreas Werner, Axel Gatzweiler, Barbara Richter, Gerhard Ehninger, Gustavo Baretton, Michael Bachmann, Pauline Wimberger, Katrin Friedrich

Affiliations

  1. Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  2. National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
  3. German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. Department of Pathology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  5. Medizinische Klinik und Poliklinik I, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany.
  6. GEMoaB Monoclonals GmbH, Dresden, Germany.
  7. Department of Gynecology, Diakonissenkrankenhaus Dresden, Dresden, Germany.
  8. Department of Gynecology, St. Joseph Stift, Dresden, Germany.
  9. Department of Gynecology, Elblandkliniken, Dresden, Germany.
  10. University Cancer Center (UCC) Carl Gustav Carus, Tumor Immunology, Technische Universität Dresden, Dresden, Germany.
  11. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.

PMID: 28903367 PMCID: PMC5589606 DOI: 10.18632/oncotarget.17523

Abstract

BACKGROUND: Prostate stem cell antigen (PSCA) has been suggested as biomarker and therapeutic target for prostate cancer. Recent advances showed that PSCA is up-regulated in other cancer entities, such as bladder or pancreatic cancer. However, the clinical relevance of PSCA-expression in breast cancer patients has not yet been established and is therefore addressed by the current study.

METHODS: PSCA-protein expression was assessed in 405 breast cancer patients, using immunohistochemistry (PSCA antibody MB1) and tissue microarrays.

RESULTS: PSCA-expression was detected in 94/405 patients (23%) and correlated with unfavorable histopathological grade (p=0.011) and increased Ki67 proliferation index (p=0.006). We observed a strong positive correlation between PSCA-protein expression and HER2/neu receptor status (p<0.001). PSCA did not provide prognostic information in the analyzed cohort. Interestingly, the distribution of PSCA-expression among triple negative patients was comparable to the total population.

CONCLUSION: We identified a subgroup of PSCA-positive breast cancer patients, which could be amenable for a PSCA-targeted therapy. Moreover, given that we found a strong positive correlation between PSCA- and HER/neu expression, targeting PSCA may provide an alternative therapeutic option in case of trastuzumab resistance.

Keywords: HER2/neu; PSCA; breast cancer; therapeutic target

Conflict of interest statement

CONFLICTS OF INTERESTS AE, GE and MB hold patents related to an anti-PSCA antibody. The remaining authors declare that no conflict of interest exists.

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. Oncol Rep. 2011 Jul;26(1):13-21 - PubMed
  3. Nature. 1984 Dec 6-12;312(5994):513-6 - PubMed
  4. Genes Chromosomes Cancer. 2012 Jan;51(1):30-41 - PubMed
  5. Ann Oncol. 2013 Jul;24(7):1792-801 - PubMed
  6. Biochem Biophys Res Commun. 2000 Sep 7;275(3):783-8 - PubMed
  7. J Immunol. 2012 Sep 15;189(6):3249-59 - PubMed
  8. N Engl J Med. 2005 Oct 20;353(16):1659-72 - PubMed
  9. Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):382-6 - PubMed
  10. Cancer Lett. 2006 May 18;236(2):229-38 - PubMed
  11. Cancer Res. 2001 Jun 15;61(12):4660-5 - PubMed
  12. Clin Cancer Res. 2002 Jun;8(6):1794-9 - PubMed
  13. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 - PubMed
  14. Prostate. 2007 Jul 1;67(10):1121-31 - PubMed
  15. Anat Cell Biol. 2012 Sep;45(3):149-54 - PubMed
  16. Mol Ther. 2009 Jun;17(6):1101-8 - PubMed
  17. PLoS One. 2012;7(11):e48866 - PubMed
  18. Prostate. 2014 Sep;74(13):1335-46 - PubMed
  19. World J Surg Oncol. 2004 May 10;2:13 - PubMed
  20. Oncol Lett. 2016 Jan;11(1):442-448 - PubMed
  21. Cancer Lett. 2009 May 18;277(2):126-32 - PubMed
  22. Nat Biotechnol. 2013 Jan;31(1):71-5 - PubMed
  23. J Urol. 2004 Mar;171(3):1117-21 - PubMed
  24. HPB (Oxford). 2011 Sep;13(9):643-50 - PubMed
  25. Cancer Res. 2002 May 1;62(9):2546-53 - PubMed
  26. Hum Gene Ther. 2014 Dec;25(12):1003-12 - PubMed
  27. Nat Genet. 2008 Jun;40(6):730-40 - PubMed
  28. Int Braz J Urol. 2015 Sep-Oct;41(5):849-58 - PubMed
  29. Clin Cancer Res. 2010 Jul 15;16(14):3533-8 - PubMed
  30. BMC Cancer. 2014 Jan 18;14:30 - PubMed
  31. Biomed Res Int. 2013;2013:648420 - PubMed
  32. Ann Oncol. 2012 Oct;23(10):2714-9 - PubMed
  33. Cancer Cell Int. 2016 Mar 15;16:20 - PubMed
  34. PLoS One. 2014 Apr 03;9(4):e93745 - PubMed
  35. J Immunother. 2007 May-Jun;30(4):396-405 - PubMed
  36. Prostate. 2011 Jun 15;71(9):998-1011 - PubMed
  37. Oncogene. 2000 Mar 2;19(10):1288-96 - PubMed
  38. BMC Cancer. 2013 Dec 30;13:615 - PubMed
  39. J Pathol. 2015 Dec;237(4):411-22 - PubMed
  40. Clin Cancer Res. 2009 Dec 15;15(24):7479-7491 - PubMed
  41. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  42. Arch Pathol Lab Med. 2007;131(1):18-43 - PubMed
  43. Cancer Res. 2001 Jun 1;61(11):4320-4 - PubMed
  44. Anticancer Res. 2015 May;35(5):2619-25 - PubMed
  45. BJU Int. 2006 Sep;98(3):668-73 - PubMed
  46. Oncotarget. 2016 May 10;7(19):27665-75 - PubMed
  47. BMC Cancer. 2010 Apr 07;10:129 - PubMed
  48. Oncol Rep. 2014 Jan;31(1):262-72 - PubMed
  49. J Cell Biochem. 2004 Feb 15;91(3):528-39 - PubMed
  50. Prostate. 2014 Sep;74(13):1347-58 - PubMed
  51. Ann Oncol. 2007 Jul;18(7):1133-44 - PubMed

Publication Types